Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Roche/Chugai's Actemra will be two of the most successful emerging novel agents in the rheumatoid arthritis drug market over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
The whole story can be read here.
No comments:
Post a Comment